We are a team of clinicians and scientists who envision change.
Ope Adeoye, MD
Dr. Opeolu Adeoye is associate professor of Emergency Medicine and Neurosurgery at the University of Cincinnati. He obtained primary training in Emergency Medicine and subsequent specialty training in acute stroke and neurocritical care. Dr. Adeoye is an experienced clinical trialist who served as Co-PI for the multicenter randomized Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke – Enhanced Regimen (CLEAR-ER) stroke trial, and is currently PI of the followup NIH-funded CLEAR-Full Dose Regimen (CLEAR-FDR) trial. Dr. Adeoye is also the PI for the University of Cincinnati Neurological Emergencies Treatment Trials (NETT) Hub and Spoke System, and Site PI for the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) II Study. Dr. Adeoye serves as medical director for the UC Stroke Team Telestroke Program.
Joseph Clark, MD
Dr. Clark is a Professor in the Department of Neurology at the University of Cincinnati and serves as an Adjunct Professor in the Department of Molecular and Cellular Physiology. In addition, he is on the faculty of UC’s Neuroscience Program and Physician Scientist Training Program. Dr. Clark also founded Xanthostat Diagnostics Limited and is its Chief Scientific Officer.He is also Co-Director of the Point of Care Center for Emerging Neurotechnologies (POC-CENT) at the University’s Center for Simulations and Virtual Environments Research. He received his undergraduate degree from Susquehanna University and holds both an M.S. in Biophysics and a Ph.D. in Physiology from Michigan State University. Dr. Clark is a recipient of several national and international awards, including receiving the 1990 Fogarty International Research Award, Best Article of 1997 by the Journal of Athletic Training, recognition for 2006 Advocate of the Year by the American Heart Association, and a Health Care Hero in 2009.
Matthew Flaherty, MD
Matthew Flaherty, MD, is a neurologist at the University of Cincinnati Neuroscience Institute, a member of the UC Stroke Team, and an associate professor of Neurology at the UC College of Medicine.Dr. Flaherty practices general neurology with an emphasis upon stroke care. Dr. Flaherty has authored many research abstracts, peer-reviewed articles, and book chapters on various topics related to cerebrovascular disease, including the prevention and treatment of ischemic and hemorrhagic stroke. Dr. Flaherty was awarded the Michael S. Pessin Stroke Leadership Prize by the American Academy of Neurology in 2009. He received his medical degree from the University of Kansas Medical School, did his residency training at the Mayo Clinic in Rochester, MN, and completed a vascular neurology fellowship at the University of Cincinnati. Since joining the University of Cincinnati, he has participated in numerous stroke-related clinical studies and research projects, including his role as a Pincipal Investigator of the “Spot Sign for Predicting and Treating ICH Growth (STOP-IT) Study”.
George Shaw, Ph.D, MD
George “Chip” Shaw is an Associate Professor of Emergency Medicine at the University of Cincinnati. He joined the Department’s faculty in 2001 and holds secondary appointments in Biomedical Engineering and Neuroscience at UC. In addition to the M.D., he received a Ph.D. in Physics from the University of Maryland (College Park) and completed a postdoctoral fellowship studying high-speed microwave devices at the Naval Research Laboratory. He has performed NIH funded research, including early development of the SENSE device, and has served as the principal investigator in both NIH funded and industry clinical trials. He serves as a reviewer for several journals, includes the Journal of Neuroscience Methods, Physics in Medicine and Biology and Critical Care Medicine.
Co–Founder and CEO
Mr. Kincaid leads the effort to bring the SENSE technology to market. He is an experienced health care entrepreneur, having taken a medical information technology company from start-up to successful exit. He has been a an active Angel investor as part of the Queen City Angels where he leads the review of many life-science investment opportunities. The QCA was recently ranked as the second most successful angel investment group in the United States. Prior to joining Sense Diagnostics, Mr. Kincaid consulted for start-up life science companies. Clients included individual companies, health care focused accelerators, incubators and universities. Dan has over 20 years experience in the health care and health insurance industries. He was a founder of Provider Synergies, a pharmaceutical management company that generated more than $2 billion in savings for state Medicaid programs during a five-year period and delivered significant returns for the company’s investors. He began his career at Anthem Blue Cross and Blue Shield where he was responsible for a wide variety of issues related to health care provider contracting, quality of care initiatives and cost management.